Extended Data Fig. 5: Kaplan–Meier curve for the time (in months) from randomization to the first primary endpoint, excluding PAD from the composite primary outcome definition. | Nature Medicine

Extended Data Fig. 5: Kaplan–Meier curve for the time (in months) from randomization to the first primary endpoint, excluding PAD from the composite primary outcome definition.

From: Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial

Extended Data Fig. 5

Spironolactone versus usual care (two-sided test), excluding PAD from the composite primary outcome. P-value level of significance = 0.05. PAD: peripheral arterial disease.

Back to article page